IPSC Century Therapeutics, Inc.
USHealthcareAs of 2026-08-24
Why IPSC matters now
Century Therapeutics, Inc. (IPSC) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.12 with +2.42% on the session and $183.5M in market capitalization; recent performance reads 1-month +8.02% and YTD +130.20%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-21.6M, and EPS of $-0.25. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -48.4%.
The latest indexable market news headline is "Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $3.00; recent insider activity includes Carr Douglas filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.75
P/S
0.00
EV/EBITDA
-2.17
DCF Value
$2.84
FCF Yield
-48.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-53.2%
ROA
-33.0%
ROIC
-36.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-21.6M | $-0.25 |
| Q4 2025 | $0.00 | $-19.2M | $-0.22 |
| FY 2025 | $109.2M | $-9.6M | $-0.11 |
| Q3 2025 | $0.00 | $-34.4M | $-0.40 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$3.00
Target (Median)
$3.00
Target Range
$2.00 - $4.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.57
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.